Donald Trump Calls on Pharmaceutical Companies to Lower Drug Prices

President Donald Trump has called on pharmaceutical companies to lower huge drug prices.

During a White House meeting with senior pharmaceutical executives President Trump told the companies to manufacture more of their drugs in the US.

However, the president also vowed to help the companies by speeding the approval of new medicines and by cutting taxes.

Donald Trump’s pledges helped to send shares in many of the biggest US drugmakers higher on January 31.

Pharmaceutical companies have faced intense criticism from US politicians – including Donald Trump – as well as insurance companies and patients’ groups over the high cost of new medicines and price hikes in some older generic drugs.

Image source Flickr

Among those attending the meeting were executives from Merck, Johnson & Johnson, Novartis, Amgen and the head of the Pharmaceutical Research and Manufacturers of America (PhRMA) lobbying group.

Donald Trump told them in the meeting: “US drug companies have produced extraordinary results for our country but the pricing has been astronomical for our country, we have to do better.

“We have to get even better innovation, and I want you to move your companies back to the United States.”

To help the drugmakers, Donald Trump said his administration was “going to be lowering taxes big league”.

“We’re going to be getting rid of regulations that are unnecessary – big league,” he added.

Donald Trump’s promise to speed up approvals by the FDA for new medicines sparked strong gains in pharmaceutical shares.

Shares in Merck and Amgen rose by about 1% while Novartis was up more than 2% on Wall Street.

Clyde is a business graduate interested in writing about latest news in politics and business. He enjoys writing and is about to publish his first book. He’s a pet lover and likes to spend time with family. When the time allows he likes to go fishing waiting for the muse to come.

This website has updated its privacy policy in compliance with EU GDPR 2016/679. Please read this to review the updates about which personal data we collect on our site. By continuing to use this site, you are agreeing to our updated policy.AcceptRejectRead More